{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:30:55Z","timestamp":1793316655913,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11136-025-03998-9","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T06:04:04Z","timestamp":1749881044000},"page":"2577-2589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychometric analysis of the Neuro-QoL Fatigue in generalized Myasthenia Gravis (gMG) using data from a phase 3 trial"],"prefix":"10.1007","volume":"34","author":[{"given":"Anthony","family":"Raborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Savord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie R.","family":"Houts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-0881","authenticated-orcid":false,"given":"Sheryl","family":"Pease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Scippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Ramchandren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"3998_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr, A. S., Cardwell, C. R., McCarron, P. O., & McConville, J. (2010). A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurology, 10, 46. https:\/\/doi.org\/10.1186\/1471-2377-10-46","journal-title":"BMC Neurology"},{"key":"3998_CR2","doi-asserted-by":"crossref","unstructured":"Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019). Myasthenia gravis. Vol. 5. Nature Reviews Disease Primers. Springer US, 1\u201319.","DOI":"10.1038\/s41572-019-0079-y"},{"key":"3998_CR3","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/14656566.2019.1682548","volume":"20","author":"C Barnett","year":"2019","unstructured":"Barnett, C., Tabasinejad, R., & Bril, V. (2019). Current pharmacotherapeutic options for myasthenia gravis. Expert Opinion on Pharmacotherapy, 20, 2295\u20132303.","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"3998_CR4","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","volume":"410","author":"J Morren","year":"2020","unstructured":"Morren, J., & Li, Y. (2020). Maintenance immunosuppression in myasthenia gravis, an update. Journal of the Neurological Sciences, 410, 116648\u2013116648. https:\/\/doi.org\/10.1016\/j.jns.2019.116648","journal-title":"Journal of the Neurological Sciences"},{"key":"3998_CR5","unstructured":"Pease S, Scippa K, Gandhi K. Assessing the suitability of the Neuro-QoL Fatigue to evaluate fatigue in patients living with Myasthenia Gravis. EAN Annual Congress. Helsinki, Finland. June 2024."},{"issue":"6","key":"3998_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns, T. M., Sadjadi, R., Utsugisawa, K., Gwathmey, K. G., Joshi, A., Jones, S., Bril, V., Barnett, C., Guptill, J. T., Sanders, D. B., Hobson-Webb, L., Juel, V. C., Massey, J., Gable, K. L., Silvestri, N. J., Wolfe, G., Cutter, G., Nagane, Y., Murai, H., \u2026 Conaway, M. (2016). International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle & Nerve, 54(6), 1015\u20131022. https:\/\/doi.org\/10.1002\/mus.25198","journal-title":"Muscle & Nerve"},{"issue":"5","key":"3998_CR7","doi-asserted-by":"publisher","first-page":"2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu, T., Meisel, A., Mantegazza, R., Annane, D., Katsuno, M., Aguzzi, R., Enayetallah, A., Beasley, K. N., Rampal, N., & Howard, J. F. (2022). Terminal complement inhibitor ravulizumab in generalized Myasthenia Gravis. NEJM Evidence, 1(5), 2100066.","journal-title":"NEJM Evidence"},{"issue":"23","key":"3998_CR8","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","volume":"78","author":"D Cella","year":"2012","unstructured":"Cella, D., Lai, J.-S., Nowinksi, C. J., Victorson, D., Peterman, A., Miller, D., Bethoux, F., Heinemann, A., Rubin, S., Cavazos, J. E., Reder, A. T., Sufit, R., Simuni, T., Holmes, G. L., Siderowf, A., Wojna, V., Bode, R., McKinney, N., Podrabsky, T., \u2026 Moy, C. (2012). Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology. Neurology, 78(23), 1860\u20131867.","journal-title":"Neurology"},{"key":"3998_CR9","unstructured":"US Food and Drug Administration (2022). Patient-focused drug development: Selecting, developing or modifying fit-for-purpose clinical outcome assessments (Draft Guidance). https:\/\/www.fda.gov\/media\/159500\/download. Accessed Sept. 18, 2023."},{"key":"3998_CR10","unstructured":"US Food and Drug Administration (2023). Patient-focused drug development: Incorporating clinical outcome assessments into endpoints for regulatory decision-making (Draft Guidance). https:\/\/www.fda.gov\/media\/166830\/download. Accessed May 5, 2024."},{"key":"3998_CR11","unstructured":"Antozzi, C., Vu, T., Ramchandren, S., et al. (in press). Efficacy and safety of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurology."},{"key":"3998_CR12","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Llyod, A., Janssen, M. F., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011). Development and preliminary testing of the new five-level version of the EQ-5D (EQ-5D-5L). Quality of Life Research, 20, 1727\u20131736.","journal-title":"Quality of Life Research"},{"issue":"7","key":"3998_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe, G. I., Herbelin, L., Nations, S. P., Foster, B., Bryan, W. W., & Barohn, R. J. (1999). Myasthenia gravis activities of daily living profile. Neurology, 52(7), 1487.","journal-title":"Neurology"},{"issue":"1","key":"3998_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"2006","unstructured":"Barohn, R. J., McIntire, D., Herbelin, L., Wolfe, G. I., Nations, S., & Bryan, W. W. (2006). Reliability testing of the Quantitative Myasthenia Gravis score. Annals of the New York Academy of Sciences, 841(1), 769\u2013772.","journal-title":"Annals of the New York Academy of Sciences"},{"key":"3998_CR15","volume-title":"flexMIRT\u00ae version 37: Flexible multilevel multidimensional item analysis and test scoring [Computer software]","author":"L Cai","year":"2024","unstructured":"Cai, L. (2024). flexMIRT\u00ae version 37: Flexible multilevel multidimensional item analysis and test scoring [Computer software]. Vector Psychometric Group."},{"key":"3998_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1037\/1082-989X.12.1.58","volume":"12","author":"RJ Wirth","year":"2007","unstructured":"Wirth, R. J., & Edwards, M. C. (2007). Item factor analysis: Current approaches and future directions. Psychological Methods, 12, 58\u201379.","journal-title":"Psychological Methods"},{"key":"3998_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/BF02293801","volume":"46","author":"RD Bock","year":"1981","unstructured":"Bock, R. D., & Aitkin, M. (1981). Marginal maximum likelihood estimation of item parameters: Application of an EM algorithm. Psychometrika, 46, 443\u2013459.","journal-title":"Psychometrika"},{"key":"3998_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02291170","volume":"38","author":"LR Tucker","year":"1973","unstructured":"Tucker, L. R., & Lewis, C. (1973). A reliability coefficient for maximum likelihood factor analysis. Psychometrika, 38, 1\u201310. https:\/\/doi.org\/10.1007\/BF02291170","journal-title":"Psychometrika"},{"key":"3998_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"L Hu","year":"1999","unstructured":"Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling, 6, 1\u201355.","journal-title":"Structural Equation Modeling"},{"key":"3998_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10705511.2011.581993","volume":"18","author":"A Maydeu-Olivares","year":"2011","unstructured":"Maydeu-Olivares, A., Cai, L., & Hernandez, A. (2011). Comparing the fit of IRT and factor analysis models. Structural Equation Modeling, 18, 333\u2013356.","journal-title":"Structural Equation Modeling"},{"key":"3998_CR21","first-page":"136","volume-title":"Testing structural equation models","author":"MW Browne","year":"1993","unstructured":"Browne, M. W., & Cudeck, R. (1993). Alternative ways of assessing model fit. In K. A. Bollen & J. S. Long (Eds.), Testing structural equation models (pp. 136\u2013162). Sage."},{"issue":"2","key":"3998_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1207\/s15327574ijt0502_4","volume":"5","author":"DJ Mundfrom","year":"2005","unstructured":"Mundfrom, D. J., Shaw, D. G., & Ke, T. L. (2005). Minimum sample size recommendations for conducting factor analyses. International Journal of Testing, 5(2), 159\u2013168. https:\/\/doi.org\/10.1207\/s15327574ijt0502_4","journal-title":"International Journal of Testing"},{"key":"3998_CR23","volume-title":"Psychometric Theory","author":"JC Nunnally","year":"1978","unstructured":"Nunnally, J. C. (1978). Psychometric Theory (2nd ed.). McGraw-Hill.","edition":"2"},{"key":"3998_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw, K. O., & Wong, S. P. (1996). Forming inferences about some intraclass correlation coefficients. Psychological Methods, 1, 30\u201346.","journal-title":"Psychological Methods"},{"key":"3998_CR25","unstructured":"Fleiss, J.L. (1986). Reliability of measurement. In: The Design and Analysis of Clinical Experiments [pp. 1\u201332]. Wiley."},{"issue":"4","key":"3998_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","volume":"6","author":"DV Cicchetti","year":"1994","unstructured":"Cicchetti, D. V. (1994). Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological Assessment, 6(4), 284\u2013290. https:\/\/doi.org\/10.1037\/1040-3590.6.4.284","journal-title":"Psychological Assessment"},{"key":"3998_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","volume":"27","author":"CD Coon","year":"2018","unstructured":"Coon, C. D., & Cook, K. F. (2018). Moving from significance to real-world meaning: Methods for interpreting change in clinical outcome assessment scores. Quality of Life Research, 27, 33\u201340.","journal-title":"Quality of Life Research"},{"key":"3998_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61, 102\u2013109.","journal-title":"Journal of Clinical Epidemiology"},{"key":"3998_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104561","volume":"72","author":"LZ Ryerson","year":"2023","unstructured":"Ryerson, L. Z., Foley, J. F., Defer, G., Cohen, J. A., Arnold, D. L., Butzkueven, H., Cutter, G., Giovannoni, G., Killestein, J., Wiendl, H., Sinks, S., Kuhelj, R., Bodhinathan, K., & Lasky, T. (2023). Exploratory clinical efficacy and patient-reported outcomes from NOVA: a randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 72, Article 104561.","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"3998_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.yebeh.2013.11.008","volume":"31","author":"D Victorson","year":"2014","unstructured":"Victorson, D., Cavazos, J. E., Holmes, G. L., Reder, A. T., Wojna, V., Nowinski, C., Miller, D., Buono, S., Mueller, A., Moy, C., & Cella, D. (2014). Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy & Behavior, 31, 77\u201384.","journal-title":"Epilepsy & Behavior"},{"issue":"1","key":"3998_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s41687-024-00743-7","volume":"8","author":"R Ataman","year":"2024","unstructured":"Ataman, R., Alhasani, R., Auneau-Enjalbert, L., Quigley, A., Michael, H. U., & Ahmed, S. (2024). The psychometric properties of the Quality of Life in Neurological Disorders (Neuro-QoL) measurement system in neurorehabilitation populations: A systematic review. Journal of Patient-Reported Outcomes, 8(1), 106.","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"4","key":"3998_CR32","doi-asserted-by":"publisher","first-page":"205521731988598","DOI":"10.1177\/2055217319885986","volume":"5","author":"LD Medina","year":"2019","unstructured":"Medina, L. D., Torres, S., Alvarez, E., Valdez, B., & Nair, K. V. (2019). Patient-reported outcomes in multiple sclerosis: Validation of the quality of life in neurological disorders (neuro-QoL\u2122) short forms. Multiple Sclerosis Journal-Experimental, Translational and Clinical, 5(4), 2055217319885986.","journal-title":"Multiple Sclerosis Journal-Experimental, Translational and Clinical"},{"issue":"1","key":"3998_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mus.24953","volume":"53","author":"TM Burns","year":"2016","unstructured":"Burns, T. M. (2016). The best of both worlds: Using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis. Muscle & Nerve, 53(1), 3\u20134. https:\/\/doi.org\/10.1002\/mus.24953","journal-title":"Muscle & Nerve"},{"issue":"7","key":"3998_CR34","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s11136-017-1644-z","volume":"27","author":"MC Edwards","year":"2018","unstructured":"Edwards, M. C., Slagle, A., Rubright, J. D., & Wirth, R. J. (2018). Fit for purpose and modern validity theory in clinical outcomes assessment. Quality of Life Research, 27(7), 1711\u20131720.","journal-title":"Quality of Life Research"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-025-03998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-025-03998-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-025-03998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:04:05Z","timestamp":1757952245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-025-03998-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3998"],"URL":"https:\/\/doi.org\/10.1007\/s11136-025-03998-9","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"15 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Raborn, A. Savord, and C. Houts are employees of Vector Psychometric Group, LLC, which received funds from Janssen Research and Development, LLC to conduct the research detailed in the manuscript. S. Pease, K. Scippa, and S. Ramchandren are employees of Johnson & Johnson companies and may hold stock or other ownership interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}